💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Empagliflozin

CHEMBL2107830 Phase 4 已批准 Small molecule
Half-Life
12.4 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
450.9 g/mol
LogP
2.0
Phase
4

This medication works by causing the kidneys to remove excess sugar from the body through urine, helping to lower blood sugar levels in type 2 diabetes. It also has proven benefits for heart and kidney health.

分子量

450.9100 g/mol

LogP

2.00

TPSA

109.00 Ų

Lipinski 五规则

符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Epilepsy Inflammatory Bowel Disease Systemic Lupus Erythematosus Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Gout Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

药物分类

A — A - Alimentary Tract and Metabolism

作用机制

Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Pharmacokinetics (PK)

Half-Life 12.4 hours

Pharmacodynamics (PD)

机制

Selective SGLT2 inhibitor reducing renal glucose reabsorption.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H27ClO7

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
可旋转键数

                        
6

                    

                    
                    
                    

                        
重原子数

                        
31

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PPARG (Peroxisome Proliferator-Activated Receptor Gamma)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Empagliflozin + Losartan
                            
                        

                        
                        
Empagliflozin and losartan can both reduce blood pressure and lower serum potassium/sodium; combined use may increase the risk of dehydration, hypotension, and electrolyte imbalance.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Empagliflozin + Hydrochlorothiazide
                            
                        

                        
                        
The combination of empagliflozin and hydrochlorothiazide can cause additive volume depletion and hypotension, and may also increase the risk of genital mycotic infections through shared glucosuria.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Empagliflozin + Ramipril
                            
                        

                        
                        
Combining empagliflozin with an ACE inhibitor such as ramipril can cause additive blood pressure reduction and volume depletion, increasing the risk of hypotension and acute kidney injury.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Empagliflozin + Furosemide
                            
                        

                        
                        
Both empagliflozin and furosemide promote natriuresis and diuresis; concurrent use can produce additive volume depletion, hypotension, and electrolyte disturbances.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
This medication works by causing the kidneys to remove excess sugar from the body through urine, helping to lower blood sugar levels in type 2 diabetes. It also has proven benefits for heart and kidney health.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective SGLT2 inhibitor reducing renal glucose reabsorption.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Empagliflozin: Half-life: 12.4 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Empagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2107830.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11949646.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.